 |
 |
|
|
|
|
|
 |
| |
|
|
 |
Opening Keynote
 |
Nora D. Volkow M.D.
Director, National Institute on Drug Abuse, National Institutes of Health
“Addiction from Scientific Knowledge to Clinical Solutions”
“Recent scientific advances have led the research community to recognize drug addiction as a chronic, relapsing brain disease characterized by compulsive drug seeking and use. Drugs of abuse disrupt normal brain communication. Repeated disruptions in the brain’s normal signaling processes can eventually lead to addiction - affecting the very circuits needed to exert good judgment and inhibitory control over actions. With these abilities compromised, the addicted person will compulsively choose drugs, even in the face of devastating life
consequences. Dr. Volkow will discuss the vast implications of drug abuse on our society and define the challenge to industry, academia, and related not-for-profits to identify new and
effective treatments.” |
Luncheon Keynote
 |
Greg Simon, J.D.
President, FasterCures/The Center for Accelerating Medical Solutions
“What you Seed Is What You Get – Making Faster Cures the Central Organizing Principle of Our Research Enterprise”
“Our current system of medical research is based on the organizing principle of studying human biology. Every part of the research culture - tenure, grant writing, fear of failure, publication delays, a conservative peer review system - all derive from that principle. In the 21st Century our challenge is to make curing diseases the central organizing
principle of our national research enterprises, with all of the cultural changes that
implies.“
|
Closing Keynote
 |
James A. Weyhenmeyer, Ph.D.
Senior Vice President for Research, Research Foundation of SUNY & Senior Vice Provost for Research & Economic Development SUNY
“Biotechnology: Bridging The Gap From Technology To Market”
“Long Island is a major reason that New York is considered one of the top states in the nation for bioscience growth. Its leaders have built a strong academic infrastructure,
a growing number of bioscience businesses and increasing government support.
Expanding the opportunities for capital investment and market opportunities for this growing industry sector in New York will be important if we are to continue to
successfully compete in the global marketplace.”
|
|
|
|
